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Healthy Elderly Subjects
What Is the Number Needed to Treat?
We thank Dr. Sigurdsson for the comment to our article (1). We
agree on the relevance of deﬁning the correct number needed to
treat (NNT) to make a balanced evaluation of the cost/beneﬁt
proﬁle of therapies. As with previous authors who used the same
formula adopted in our meta-analysis (2), our aim was to calculate
the NNT per year, dividing the overall NNT calculated for
the entire trial duration by the length of follow-up. We agree
with Dr. Sigurdsson that this method may represent an over-
simpliﬁcation because this calculation assumes that the effect of
the treatment (relative risk reduction) is constant over time and
that events occur at a constant rate over time (3).
Therefore, as suggested by Dr. Sigurdsson, we report here the
NNT for the mean follow-up of our meta-analysis (3.5 years)
calculated by using the following formula: NNT ¼ 1/ARR ¼
1/(CER – EER), where ARR is the absolute risk reduction, CER
is the control event rate, and EER is the experimental event rate
(4). In the studies assessing the occurrence of myocardial infarction,
216 events were reported in the statin group and 312 in theplacebo group. With 7,939 patients enrolled in the statin group
and 7,985 in the placebo one, the NNT was 83. In the studies
assessing the occurrence of stroke, 8,111 patients were enrolled in
the statin group and 8,211 in the placebo group. With 169 events
reported in the statin group and 227 in the placebo group, the
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